Sign up
Pharma Capital

Scancell Holdings wins Japanese patent protection

It follows on from similar awards in key markets such as the US, Europe, South Africa and Australia
patent spelled out in coloured letters
The company now has protection in many of its key markets

Scancell Holdings PLC (LON:SCLP) shares rose on Monday after the group revealed it has won Japanese patent protection for its Moditope immunotherapy platform.

It follows on from similar awards in key markets such as the US, Europe, South Africa and Australia, and acceptance for a grant in China.

READ: Scancell strengthens IP with two “important” patent grants in US and Europe

“We look forward to continuing to advance Modi-1, the first product from this platform, towards clinical development," said chief executive, Dr Cliff Holloway.

Moditope is one of two platforms the company has developed – the other is ImmunoBody, which has spawned SCIB-1 and SCIB-2, which target and stimulate existing cells that make up the body’s defence mechanisms.

The UK group is planning to use SCIB1 in harness with Merck’s Keytruda checkpoint inhibitor to treat patients with advanced melanoma.

In mid-morning trading, shares in Scancell were up 2% at 5.2p.

 -- Adds share price --

Ian_55ae0ddd437b7.jpg
Why Invest In Scancell Holdings PLC? Read More Here

Register here to be notified of future SCLP Company articles
View full SCLP profile View Profile
View All

Related Articles

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.